アルツハイマー病における刺激に対する現行および新興の薬理学的アプローチ:新しいおよび再利用された治療法のナラティブレビュー
Charles Smoller1, Emily Schiller2, Kyla Yamashita3
1Division of Geriatric Psychiatry, Department of Psychiatry and Behavioral Neuroscience, Saint Louis University School of Medicine, 1438 S. Grand Boulevard, St. Louis, MO, 63104, USA.
Drugs
|September 6, 2025
まとめ
アルツハイマー病 (AD) のアジテーションに対する薬理学的治療法は,ブレクスピプラゾールやリスペリドンのような承認された薬剤を強調してレビューされています. この困難なADの症状の管理に より安全で効果的な方法を 探す研究が続けられています
科学分野:
- 神経科学と薬理学
- 高齢 医学
- アルツハイマー病の研究
背景:
- 興奮はアルツハイマー病 (AD) の流行し,挑戦的な行動症状です.
- 非薬学的な介入は第一線ですが,ADの刺激管理にはしばしば不十分です.
- 過去に使用された抗精神病薬は,ADの興奮に対する安全性と有効性に関する懸念を示しています.
研究 の 目的:
- アルツハイマー病 (AD) のアジテーションに対する現在の薬理学的治療法をレビューする.
- ADの刺激管理のための新しい薬剤候補に重点を置く.
- 薬の開発における臨床的利益と課題が限られている薬剤を分析する.
主な方法:
- 既存の科学文献の解説レビュー
- 抗発作薬,SSRI,カンナビノイドを含む様々な薬物クラスに関する発見の統合.
- アルツハイマー病の刺激に対する承認された治療法と試験中の治療法の検討
主要な成果:
- ブレックスピプラゾールとリスペリドンは有効性を示し,特定の地域で規制承認されています.
- 承認された薬剤の長期的な安全性および有効性に関する懸念は依然として存在します.
- 他のいくつかの薬剤は調査中ですが,現在承認されていません.
結論:
- 現在,アルツハイマー病の薬学的選択肢は限られている.
- この脆弱な集団に対する 安全で効果的な治療法を見つけるには 継続的な研究が不可欠です
- ADの刺激に対する新しい治療法の開発は,依然として重要な臨床的課題です.
関連する概念動画
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Drug Therapy
96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
96
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Antidepressant Drugs: MAOIs and Other Agents
337
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
337
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206


